Anlotinib plus benmelstobart and chemotherapy are effective in ES-SCLC

IF 81.1 1区 医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2024-07-29 DOI:10.1038/s41571-024-00931-w
Diana Romero
{"title":"Anlotinib plus benmelstobart and chemotherapy are effective in ES-SCLC","authors":"Diana Romero","doi":"10.1038/s41571-024-00931-w","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41571-024-00931-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
安罗替尼联合苯美司托巴特和化疗对ES-SCLC有效
广泛期小细胞肺癌(ES-SCLC)患者通常接受铂类化疗加免疫检查点抑制剂(ICI)作为一线疗法,但疾病复发是一个令人担忧的问题。现在,来自III期ETER701试验的数据表明,抗血管生成药物安罗替尼加上抗PD-L1抗体本迈斯托巴特和化疗的联合疗法在这种情况下具有良好的疗效。患者被随机分配接受安罗替尼+苯美司巴特和化疗(三联方案;n = 246)、安罗替尼+安慰剂和化疗(双联方案;n = 245)或双安慰剂+化疗(试验设计时中国的标准治疗方案)(n = 247)。无进展生存期(PFS)和总生存期(OS)为共同主要终点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
99.40
自引率
0.40%
发文量
114
审稿时长
6-12 weeks
期刊介绍: Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
期刊最新文献
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now? On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients? Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress Cadonilimab is effective and safe in recurrent cervical cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1